Marie Mayenga
Suresnes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.
The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.
Journal: Breathe (Sheffield, England)
Published: March 02, 2024
Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 23, 2023
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Journal: Cancer immunology, immunotherapy : CII
Published: February 27, 2023
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Journal: Cancer immunology, immunotherapy : CII
Published: August 11, 2022
Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.
Journal: Cancer immunology, immunotherapy : CII
Published: February 28, 2022
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 01, 2020
Lorlatinib - Induced pulmonary arterial hypertension.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 23, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026